XBIO Xenetic Biosciences, Inc.: Price-to-Projected Revenue Ratio

Symbol and logo of brand Xenetic Biosciences Inc. (XBIO)

The forward P/S trend for Xenetic Biosciences (XBIO) is based on early preclinical tests of enzyme platforms for tumor combat. The company's current potential relies on the XCART personalized T-cell therapy system, while business development is accelerating through partnerships with medical centers to enhance immunotherapy. Meanwhile, 1.20 represents a fresh level value, helping to assess market expectations for the issuer's future revenue.

Xenetic Bio - XBIO Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/17/2026)

Analytical breakdowns for Xenetic Biosciences

- company stock capitalization data:
Analysis of all company metrics:Xenetic Biosciences, Inc. (XBIO)
Product sample of xeneticbio.com

Xenetic Biosciences (XBIO) resilience to volatility depends on the monetization of licenses and oncology platforms, which directly impacts the market valuation of expected cash flows. Analyzing the forward P/S trend, an investor can discern the value of a unit of future revenue, where sharp spikes in the line signal the risk of low asset liquidity when attempting a rapid exit from a position during a crisis.

Key competitors

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|Mural Oncology (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|OKUR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CytoMed Therapeutics Limited|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward P/S Multiple tharimmune.com (THAR)|Advanced Biomed Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales GNPX|Calidi Biotherapeutics, Inc. - Forward P/S Multiple|Sunshine Biopharma (SBFM) - Forward Price-to-Revenue Multiple|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple